



November 18, 2020

The Manger - Listing

BSE Limited

Corporate Relationship Dept., 1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

National Stock Exchange of India Ltd.

Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Disclosure of Related Party Transactions

Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended September 30, 2020 for your information and records.

For **AstraZeneca Pharma India limited**

Pratap Rudra

Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000

FAX : +91 80 6774 8857

CIN : L24231KA1979PLC003563

WEB : www.astrazeneca.com/india

FACTORY

12th Mile on Bellary Road
Venkatata, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000

FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited

Disclosure of related party transactions for the half year ended 30 September, 2020

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

(All amounts in Rs.million, except per share and share data)

(i) Names of related parties and related party relationship

(a) Related parties where control exists and/or where transactions have occurred:

| Name of the entity | Name of relationship |
|--|--|
| Holding Company | AstraZeneca Pharmaceuticals AB, Sweden |
| Holding Company of AstraZeneca Pharmaceuticals AB, Sweden | AstraZeneca AB, Sweden |
| Holding Company of AstraZeneca AB, Sweden | AstraZeneca Treasury Limited, United Kingdom |
| Ultimate Holding Company | AstraZeneca Plc, United Kingdom |
| Fellow subsidiaries with whom the company had transactions during the year | AstraZeneca Singapore Pte Ltd, Singapore AstraZeneca Pharmaceuticals LP, USA AstraZeneca UK Limited, United Kingdom P.T. AstraZeneca Indonesia AstraZeneca Pty Ltd, Australia AstraZeneca SDN Bhd, Malaysia AstraZeneca India Private Limited, India |
| Employees' Benefit Plans | AstraZeneca Pharma India Limited Employees Gratuity Fund Trust AstraZeneca Pharma India Limited Management Staff Provident Fund Trust AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust |

b) Key Management Personnel

| | |
|--|---|
| - Managing Director | Mr. Gagandeep Singh Bedi |
| - Director and Chief Financial Officer | Mr. Rajesh Marwaha |
| - Non-Executive Directors | Ms. Weiyang Sarah Wang Mr. Ankush Nandra (appointed w.e.f 18 May 2020) Mr. Ian John Parish (resigned w.e.f 18 May 2020) |

c) Independent Directors

Mr. Narayan K Seshadri
Ms. Revathy Ashok
Ms. Kimsuka Narasimhan

(ii) Details of the transactions with the related parties during the period 01 April 2020 to 30 September 2020 :

| | |
|---|---------|
| Purchase of materials and traded goods | |
| AstraZeneca UK Limited, United Kingdom | 1,312.0 |
| AstraZeneca AB, Sweden | 134.9 |
| Payment towards reimbursement of expenses | |
| AstraZeneca UK Limited, United Kingdom | 8.4 |
| AstraZeneca Pty Ltd, Australia | 5.5 |
| Sale of services | |
| AstraZeneca AB, Sweden | 226.1 |
| Recovery of reimbursable expenses | |
| AstraZeneca UK Limited, United Kingdom | 65.9 |
| P.T. AstraZeneca Indonesia | 18.0 |
| AstraZeneca Singapore Pte Ltd, Singapore | 9.4 |
| AstraZeneca Pharmaceuticals LP, USA | 20.0 |
| AstraZeneca SDN Bhd, Malaysia | 5.8 |
| Contribution to Trusts | |
| AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust | 6.4 |

(iii) (a) Transactions with Key Management Personnel

| | |
|--------------------------------------|-------------|
| Salary and perquisites | |
| Short-term employee benefits | 38.5 |
| Long-term employee benefits | 8.2 |
| Post employment benefits | 19.0 |
| Employee share compensation expenses | 2.7 |
| | 68.4 |

(iii) (b) Transactions with Independent Directors

| | |
|--|-----|
| Sitting fees paid to independent directors | 1.2 |
|--|-----|

(iv) Details of balances receivable from and payable to related parties as at 30 September, 2020 are as follows:

| | |
|--|--------------|
| Other current financial assets | 107.5 |
| AstraZeneca UK Limited, United Kingdom | 16.2 |
| AstraZeneca Pharmaceuticals LP, USA | 10.2 |
| AstraZeneca Singapore Pte Ltd, Singapore | 4.7 |
| P.T. AstraZeneca Indonesia | 3.9 |
| AstraZeneca SDN Bhd, Malaysia | 1.7 |
| AstraZeneca AB, Sweden | 70.8 |
| Trade receivables | 73.4 |
| AstraZeneca AB, Sweden | 73.4 |
| Trade payables | 426.4 |
| AstraZeneca UK Limited, United Kingdom | 360.8 |
| AstraZeneca AB, Sweden | 62.7 |
| AstraZeneca Pty Ltd, Australia | 2.9 |